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OBJECTIVES: Interleukin-23 (IL-23) has emerged as a new therapeutic target for the treatment of inﬂammatory bowel disease
(IBD). As biomarkers of disease state and treatment efﬁcacy are becoming increasingly important in drug development, we
sought to identify efﬁcacy biomarkers for anti-IL-23 therapy in Crohn’s disease (CD).
METHODS: Candidate IL-23 biomarkers, downstream of IL-23 signaling, were identiﬁed using shotgun proteomic analysis of
feces andcolon lavages obtained from ashort-term mouse IBD model (anti-CD40Rag2
 / )treated preventively withmonoclonal
antibodies (mAbs) to the IL-23 receptor (IL-23R). The biomarkers were then measured in an IBD T-cell transfer model treated
therapeutically with a mAb to IL-23 (p19), conﬁrming their association with IBD. To assess the clinical relevance of these
markers, we assessed their concentrations in clinical serum, colon tissue, and feces from CD patients.
RESULTS:Weidentiﬁed57proteinsupordownregulatedindiseasedanimalsthatreturnedtocontrolvalueswhenthemicewere
treatedwithmAbstoIL-23R.Amongthose,S100A8,S100A9,regeneratingprotein3b(REG),REG3c,lipocalin2(LCN2),deletedin
malignant tumor 1 (DMBT1), and macrophage migration inhibitory factor (MIF) mRNA levels correlated with disease score and
dose titration of mAbs to IL-23R or IL-23(p19). All biomarkers, except DMBT1, were also downregulated after therapeutic
administration of mAbs to IL-23(p19) in a T-cell transfer IBD mouse model. In sera from CD patients, we conﬁrmed a signiﬁcant
upregulation of S100A8/A9 (43%), MIF (138%), pancreatitis-associated protein (PAP, human homolog of REG3b/c; 49%), LCN2
(520%), and CCL20 (1280%), compared with control samples, as well as a signiﬁcant upregulation of S100A8/A9 (887%), PAP
(401%), and LCN2 (783%) in human feces from CD patients compared with normal controls.
CONCLUSIONS: These studies identify multiple protein biomarkers downstream of IL-23 that could be valuable tools to assess
the efﬁcacy of this new therapeutic agent.
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INTRODUCTION
Inﬂammatory bowel disease (IBD) is a gastrointestinal
disorder that can manifest as Crohn’s disease (CD) and
ulcerative colitis.
1 Interleukin-23 (IL-23) is a heterodimeric
cytokine
2composedofap40subunit,sharedwithIL-12,anda
unique p19 subunit. IL-23 acts through a heterodimeric
receptor comprising an IL-12Rb1 chain and a unique IL-23
receptor (IL-23R) chain.
3 IL-23(p19)- or IL-23R-deﬁcient mice
are resistant to IBD,
4 and the inhibition of IL-23 by anti-p19
neutralizing monoclonal antibodies (mAbs) blocks organ-
speciﬁcautoimmuneinﬂammation.
5–8Emphasizingtheroleof
the IL-23 pathway in IBD, IL-23(p19), IL-12(p40), and IL-17A
expression is elevated in human inﬂamed gut from CD and
ulcerative colitis patients,
9,10 and the p.Arg381Gln allele
polymorphism of IL-23R is associated with protection from
CD and ulcerative colitis.
11 Moreover, that particular mutation
is a loss of receptor function that reduces STAT3 phosphory-
lation upon stimulation with IL-23, and decreases the number
of IL-23 responsive T-cells.
12 Overall, these accumulating
experimental and clinical data have pointed to IL-23 as a new
therapeutic target for the treatment of IBD.
13
One of the major pitfalls resulting in failure of new thera-
pies has been a lack of efﬁcacy biomarkers in place before
starting drug development.
14 Because of this, objective and
robust target-engagement biomarker conﬁrming that the drug
has bound its target in a functional manner, and efﬁcacy
biomarkers to guide the drug-dose selection in clinical trials
have become an integral part of drug development.
14 The
most attractive target engagement and efﬁcacy biomarkers
are those in which changes occur early after the interaction
of the drug with its target, and whose expression reﬂects
the immediate downstream effects of target engagement,
conﬁrming a positive effect of therapeutic intervention. This is
critical for toxicology studies in which the drug target is a low
abundantcytokine,whichisundetectableinnormalpatients:it
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Discovery of possible target engagement and efﬁcacy
biomarkers can be carried out in animal models in which a
treatment group is included. The resulting candidate protein
biomarkers can be subsequently veriﬁed in a large number of
samples with higher throughput techniques, such as western
blot or enzyme-linked immunosorbent assay (ELISA) on
human plasma/serum or other clinically relevant and acces-
sible samples.
The purpose of the present study was twofold. First, we
evaluated the preventive effect of neutralizing mAbs to IL-23R
in the anti-CD40 Rag2
 /  T-cell-independent IBD mouse
model and compared it to the previously described inhibition
by mAbs to IL-23(p19).
8 This mouse model recapitulates the
alterations in the innate immune response that contributes to
disease triggering in human IBD. Anti-IL-23R treatment effects
onweightloss,inﬂammationofthecoloniclaminapropria,and
cytokinesandchemokineslevelswereevaluated.Second,we
sought to identify efﬁcacy biomarkers for anti-IL-23 therapy in
CD using the same animal model. The candidate biomarkers
were then conﬁrmed in a T-cell-dependent mouse model of
IBD, as T cell are essential in maintaining intestinal inﬂam-
mationin humandisease. Lastly, the mechanism ofregulation
of the candidate biomarkers was analyzed in vitro using
human epithelial cell line, and the biomarkers were conﬁrmed
in human-derived samples from normal and CD patients.
METHODS
Anti-CD40 IBD mouse model. C57BL/6 Rag2
 /  (recombi-
nase-activating gene 2 deﬁcient) mice (Taconic Farm,
Hudson, NY) were used at 48–12 weeks of age. Animals
were housed under speciﬁc pathogen-free conditions and
kept in microisolators with ﬁltered air at Schering-Plough
Biopharma (Palo Alto, CA). Conventional animal chow and
water were provided ad libitum. One day before disease
induction, mice (N¼4 per group) were injected subcuta-
neously with anti-IL-23R mAbs (Schering-Plough Biopharma,
clone 21A4), at 60mg/kg, or with an IgG1 control antibody
(clone 27F11) at 60mg/kg. At day 0, mice were administered
intravenously with 50mg of anti-CD40 (IgG2a, monoclonal Ab
FGK45) to induce IBD.
15 The naı ¨ve group did not receive any
treatment. Mice were killed by carbon dioxide asphyxiation
at day 1, 3, 5, or 7. Plasma was collected for ELISA and
multiplex serum analysis. Colons were dissected and the
preformed feces were extracted and snap-frozen for further
analysis. Two centimeter of colon, proximal to the cecum,
was collected and treated as follows: (1) ﬁxed in 10% neutral
buffered formalin, parafﬁn-embedded and tissue sections
stained with hematoxylin and eosin to evaluate tissue
pathology; (2) snap-frozen in liquid nitrogen for further RNA
extraction; or (3) placed in ice-cold, calcium-, magnesium-
and phenol red-free Hank’s balanced salt solution (HBSS) for
the separation of epithelial cells from lamina propria. All
animal procedures were approved by the Institutional Animal
Care and Use Committee of Schering-Plough Biopharma, in
accordance with guidelines of the Association for Assess-
ment and Accreditation of Laboratory Animal Care.
T-cell transfer model. C3H.SCID mice were obtained from
The Jackson Laboratory (Bar Harbor, ME) and housed in the
University of Alabama animal facility. Cecal bacterial
antigens (CBA) and CBA-speciﬁc T cells were prepared as
previously described.
16 A total of 1 10
6 cecal bacterial
antigen-speciﬁc T cells were injected into groups of 3–5
C3H.SCID mice intravenously. Adoptive transfer of anti-CD3
activated T cells was used as a control. Anti-IL-23p19 mAb
or control mAb was administered intraperitoneally (100mg/
mouse) on the same day as cell transfer and weekly there-
after for the preventive study and from week 4–8, weekly,
in the therapeutic study. Two months later or at earlier time
points based on the requirement of experiments, the mice
were killed and histopathology examined. In addition, total
RNA was recovered from the colon of each mouse for real-
time reverse-transcription PCR.
All studies were approved by the Institutional Animal Care and
Use Committee of the University of Alabama at Birmingham.
ELISA and luminex. Tumor necrosis factor-a (TNF-a) and
IL-17A were measured using multiplex serum analysis (Millipore
Corporation, Billerica, MA). S100A8/A9 (Calprotectin) ELISA
kit was from Hycult Biotechnology (Uden, The Netherlands)
and the pancreatitis-associated protein (PAP) kit from
Dynabio SA. (Marseille, France). Mouse IL-22 and human
migration inhibitory factor (MIF), lipocalin 2 (LCN2), and
CCL20/MIP-3a were Quantikine kits from R&D systems
(Minneapolis, MN). For human feces, phosphate-buffered
saline (containing protease inhibitors ‘‘Complete’’ from
Roche, Penzberg, Germany) was added to feces (w/w).
Samples were vortexed, incubated under agitation for 2h at
41C, and spun 20min at 2,000g Supernatant was collected
and spun at 16,000g for 15min at 41C. Clear supernatant
was collected and stored at  801C until ELISA analysis.
Shotgun proteomic analysis. See Supplementary Material.
Epithelial cell and lamina propria separation. Colons
were opened longitudinally, rinsed in ice cold HBSS calcium-,
magnesium- and phenol red-free, cut in pieces and incu-
bated under agitation for 20min at 371C in cell dissociation
buffer (HBSS calcium-, magnesium- and phenol red-free
supplemented with 5mM EDTA and 10mM HEPES).
Samples were vortexed for 1min and the supernatant
containing the epithelial cells was spun at 2,000g. Cell
pellets were stored at  801C, until protein extraction.
This epithelial cell enrichment process was repeated twice.
Cell pellets and remaining colons (LP) were stored at  801C,
until protein extraction.
Cell culture. HT-29 primary human colonic epithelial cells
(ATCC, St Cloud, MN) were grown in RPMI 1640 supple-
mented with 10% fetal bovine serum, 100U/ml penicillin and
100mg/ml streptomycin. Cells were starved overnight in
serum-free RPMI before stimulation with cytokines. Human
IL-17A, IL-22, and TNF-a (R&D Systems) were added to the
culture at 20ng/ml in fresh serum-free medium. Human IL-23
(Schering-Plough Biopharma) was added at 50ng/ml. Cells
were then incubated for 24–48h, at 371C. Supernatants
were harvested and analyzed by ELISA. For RNA extraction,
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with the RNeasy Mini kit (Qiagen, Valencia, CA).
Western blots. For feces, EC, and LP, proteins were
extracted in lysis buffer (25mM Tris pH 8.8/0; 4% SDS).
Thirty micrograms of proteins from EC and LP were labeled
with Cy5 (1ml, diluted 1/20) for 20min on ice. For feces, the
quantity of proteins labeled was based on the estimation
of protein concentration done by SyproRuby staining
(cf. shotgun proteomic analysis). Proteins were separated
on SDS–polyacrylamide gel electrophoresis and electro-
transferred onto polyvinylidene diﬂuoride. Membranes were
scanned using a Typhoon 9,400 imager (GE Healthcare,
Piscataway, NJ) to assess the amount loaded in each
lane. After blocking in 5% milk in TBST (10mM Tris, pH 7.5,
150mM NaCl, 0.1% Tween 20) for 1h at room temperature,
membranes were probed with the different antibodies at
1mg/ml, incubated with appropriate HRP-linked secondary
antibodies, and signal was detected using the ECL plus kit
from GE Healthcare. Band intensities were estimated with
Image J 1.39 (NIH). MIF (clone FL-115) and DMBT1 (deleted
in malignant tumor 1; Clone P-20) were from Santa Cruz
Biotechnology (Santa Cruz, CA); S100A8 (AF3059) and
LCN2 (AF1857) antibodies from R&D Systems; and REG3g
antibodies were from Schering-Plough Biopharma.
Real-time reverse-transcription PCR. DNase-treated
total RNA was reverse-transcribed using Superscript II
(Invitrogen, Carlsbad, CA) according to manufacturer’s
instructions. Primers were designed with Primer Express
(PE Biosystems, Foster City, CA) or obtained commercially
from Applied Biosystems (Carlsbad, CA). The real-time PCR
were performed as described.
17
Clinical samples. Serum samples were obtained from
Bioreclamation (East Meadow, NY), which works directly
with Institutional Review Boards to organize and collect
specimens from disease state patients. Colon biopsies were
obtained from the Mayo Clinic (Rochester, MN; see Supple-
mentary Table S2 for patient characteristics). The study was
approved by the Institutional Review Board of the Mayo Clinic,
and all patients included provided written informed consent.
Statistics. Weight, cytokine, and western-blot intensity were
analyzed with Prism 3 software (GraphPad Software, La
Jolla, CA). P values were calculated with a Mann–Whitney
non-paired t-test. The multivariate discriminant analysis was
performed with JMP (SAS, Cary, NC).
RESULTS
Proteomic proﬁling in the anti-CD40 induced colitis
Rag2
 /  mice. One day after a preventive treatment with
either anti-IL-23R mAb or an isotype control, autoimmune
colitis was induced in Rag2
 /  mice by direct activation
of inﬂammatory dendritic cells and macrophages with a
CD40 agonist that mimics activated T cells (Supplementary
Figure S1).
8 Isotype-control-treated animals showed intense
histological signs of colitis from day 1 to day 7, which were
associated with epithelial hyperplasia and leukocyte inﬁl-
tration within the lamina propria. Treatment with a mAb to
IL-23R completely prevented this intestinal inﬂammation
(Figure 1a). Consistent with leukocyte inﬁltration, control
animals treated with an isotype mAb had increased colon
expression of innate immune cell markers such as CD11b,
lactoferrin, and neutrophil elastase, and a marked increase
of pro-inﬂammatory cytokines such as IL-6 and interferon-g
(Supplementary Figure S2A). Treatment with mAbs to IL-23R
prevented these increases. Anti-CD40 treatment also rapidly
induced IL-22, IL-17A, and TNF-a gene expression in colon
tissue (Figure 1b), and treatment with mAbs to IL-23R
blocked these increases locally. IL-22 protein concentrations
were also increased in the plasma 1 day after the challenge
with the CD40 agonist, and this increase was inhibited
by treatment with mAbs to IL-23R. In contrast, TNF-a plasma
concentrations were unaffected by the treatment (Supple-
mentary Figure S2B). Systemic production of IL-17A was
undetectable.
To identify protein biomarkers secreted in the lumen of
the gut that were modulated in the disease state and returned
to control values by treatment with mAbs to IL-23R, we
performed a shotgun proteomic analysis
18 of proteins extracted
from colon lavages and feces. Before mass spectrometry
analysis, proteins were separated by SDS–polyacrylamide
gel electrophoresis to decrease the complexity of the
samples. Numerous proteins appeared in multiple bands,
at different molecular weights (e.g., DMBT1, carbonic
anhydrase 1, neutrophilic elastase), suggesting a possible
degradation and/or various post-translational modiﬁcations in
the colon lumen. Using this approach, we identiﬁed peptides
from B130 unique proteins, 57 of which were modulated in
the disease state but remained at control values by treatment
with mAbs to IL-23R (Supplementary Table S1). These
proteins belonged to different functional families: as enzymes
(25%), peptidases (10%), kinases (9%), transporters (5%)
and others (51%). Among them, S100A8, S100A9, Reg3b,
Reg3g, DMBT1, MIF, and LCN2 were selected for further
validation. Our selection criteria included an up- or down-
regulation proﬁle in the disease state compared with naı ¨ve
animals, a reversion by the anti-IL-23R treatment, a known
association with IBD pathology and/or IL-23 biology, and
availability of reagents to quantify them.
Candidate biomarkers in a T-cell-independent mouse
model of model. As our shotgun proteomic analysis is a
semi-quantitative approach, we veriﬁed the differences
observed in naı ¨ve, diseased, and treated by mAbs to IL-
23R- or IL-23(p19) mice using real-time reverse-transcription
PCR analysis of colon tissue. S100A8, S100A9, REG3b,
REG3g, LCN2, and MIF gene expression levels were
upregulated at day 1 and sustained at a high level until day
7 in isotype-control-treated animals (Figure 1c). Treatment
by mAbs to IL-23R prevented the upregulation of REG3b and
REG3g at day 1, whereas it only showed effects at day 3 for
S100A8, S100A9, LCN2, and MIF (Figure 1c). DMBT1
transcripts were signiﬁcantly downregulated at day 7 in the
mice treated by mAbs to IL-23R compared with the one
treated by the isotype control (Figure 1c). The upregulation of
S100A8 and Reg3g proteins could be conﬁrmed by western
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treated by mAbs to IL-23R (Figure 1d), suggesting that in
addition to S100A8/A9 (calprotectin), a well-known fecal marker
of IBD,
19 Reg3g is also stable enough to be measured in
feces. Reg3g and DMBT1 were upregulated in colon epi-
thelial cells during disease (Figure 1e) but were undetectable
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was increased in diseased animals, could only be detected
in the lamina propria (Figure 1f). Protein concentration of all
the candidate biomarkers were maintained at control values in
mice treated by mAbs to IL-23R.
In addition, these biomarker transcripts were monitored in
dose titration of mAbs to IL-23R and IL-23(p19), and all
showed a dose-dependent response with either mAbs
treatment in mouse proximal colonic tissue (Supplementary
Figure S3A and Supplementary Figure S4A). Three mg/kg of
mAbs to IL-23R decreased the expression of S100A8,
S100A9,MIF,REG3g,andLCN2transcriptstocontrolvalues,
whereas 30mg/kg were needed for REG3b and DMBT1.
Remarkably, the disease score measured in the proximal
colon was 0 at both 3 and 30mg/kg, reﬂecting complete
protection from the disease as measured histologically
(Supplementary Figure S3B). The mAbs to IL-23(p19) had a
lower afﬁnity than the mAbs to IL-23R (in house data), so
animals were treated with larger doses of mAbs to IL-23(p19)
to achieve complete disease protection. In all, 120mg/kg of
mAbs to IL-23(p19) decreased the amount of expressed
mRNA of all the selected biomarkers to control values
(SupplementaryFigure S4A),aswellascompletelyprotecting
the mice from colonic disease as assessed histologically
(Supplementary Figure S4B).
Candidate biomarkers in a T-cell-dependent mouse
model of colitis. The anti-CD40 model is a T-cell-indepen-
dent model in which the innate immune system is activated to
induce colitis. As T cells are also involved in human disease,
we assessed the validity of the candidate biomarkers in the
T-cell-dependent colitis mouse model established by Elson
et al.
6 In these mice, adoptive transfer of Bir14 CD4þ T cells
to SCID recipients, colitis is established over several weeks,
allowing us to evaluate candidate biomarker gene expression
in the colon with both prophylactic and therapeutic treat-
ments by mAbs to IL-23(p19); (Figure 2a). Control recipient
mice receiving anti-CD3 activated T cells did not develop
colitis,
6 whereas mice receiving pathogenic T cells deve-
loped intense colonic inﬂammation, which was associated
with an increase of IL-17A, IL-22, and TNF-a gene expres-
sion (Figure 2a). As in the anti-CD40 IBD model, S100A8,
S100A9, REG3b and g, LCN2, and MIF transcripts increased
with colitis, and treatment by mAbs to IL-23(p19) mAbs
administered on the same day as cell transfer prevented
this upregulation (Figure 2a). Therapeutic administration of
mAbs to IL-23(p19) from week 4 after disease induction also
downregulated our set of biomarkers (Figure 2b), except for
DMBT1, which was upregulated in diseased animals but
unaffected at the transcript level by treatment.
Candidate biomarker reguation by IL-22, IL-17A, and
TNF-a in HT-29 human colonic epithelial cells. IL-17A
and IL-22 are directly downstream of IL-23.
17 The major cell
types in the gut mucosa responsive to IL-17A and IL-22
stimulation are colonic epithelial cells.
20 Therefore, to assess
the relationship of the candidate IBD biomarkers to IL-23
biology, we stimulated human HT-29 colonic epithelial cells
with IL-22 and IL-17A. As TNF-a is a powerful activator of
epithelial cells and anti-TNF-a treatment is the standard
therapy for CD
21,22 we also used TNF-a alone or in combi-
nation with IL-17A or IL-22. IL-23 alone was not able to
modulate any of the markers (Figure 3), consistent with
the absence of IL-23R in HT-29 cells (Supplementary
Figure S5C). The combination of IL-22 and IL-17A modestly
increased S100A8 and S100A9 transcripts and adding TNF-a
to IL-22 and IL-17A led to a substantial synergistic effect
(Figure 3a). The combination of IL-22 and IL-17A was the
most potent in increasing DMBT1 expression (Figure 3a).
The combination of IL-22 and IL-17A moderately increased
PAP (the human homolog of Reg3b/g) protein concentration
(Figure 3b) and the addition of TNF-a further increased its
expression at 24h and 48h after treatment (Figure 3b). In
contrast to our results in the mouse model, LCN2 expression
was detected in human colonic epithelial cells and synergis-
tically accumulated in the cell supernatant after treatment
with the combination of IL-22 and IL-17A, IL-17A and TNF-a,
as well as in the presence of IL-22, IL-17A, and TNF-a
(Figure 3b).
CCL20/MIP-3a is markedly elevated in colonic epithelial
cells from IBD patients, and this elevation can be induced by
TNF-a.
23 We conﬁrmed that TNF-a alone increased CCL20/
MIP-3a,buta signiﬁcantsynergistic effectwasobserved upon
adding IL-22, IL-17A, and TNF-a simultaneously after 24 and
48h of stimulation (Figure 3b).
IL-17F, IL-21, and IL-26 are also secreted by Th-17 cells,
17
and IL-21R and IL-26R are expressed by HT-29 cells.
24,25 We
tested the ability of these three cytokines to increase the
expression of the candidate biomarkers in the presence of
IL-17A, IL-22, and TNF-a. None of them was essential for
biomarker expression (Supplementary Figure S5).
Taken together, these results show that S100A8/A9, PAP,
LCN2, DMBT1, and CCL20/MIP-3a are regulated by IL-17A,
IL-22, and TNF-a in human epithelial cells.
Expression of potential IL-23-associated biomarkers in
patients with Crohn’s disease. To translate our ﬁndings
from the mouse IBD models to human disease, we measured
by ELISA the serum concentration of our biomarkers in
normal subjects and patients with active CD (see Supple-
mentary Table S2 for patient characteristics). Several
Figure 1 Candidate biomarker gene expression and protein concentration in mouse colon tissue or feces of a T-cell-independent model. One day before disease
induction, Rag2
 /  mice were injected subcutaneously with isotype control (at 60mg/kg) or anti-interleukin(IL)-23R neutralizing antibodies (at 60mg/kg). On the day of
disease induction, mice were injected with 50mg of anti-CD40 mAbs intravenously to induce immune-mediated colitis (see Methods). Mice were killed at days 1, 3, 5, and 7
(N¼4 per group). (a) Hematoxylin and eosin staining of proximal colon. The dashedlines indicate mucosal inﬂammation. Real-time reverse-transcription PCR analysis of( b)
IL-22, IL-17A, and tumor necrosis factor-a (TNF-a), (c) S100A8, S100A9, REG3b, REG3g, DMBT1, LCN2, and MIF transcripts in mouse proximal colon. Results are
presented relative to ubiquitin transcripts (RU, relative units). (d) Western blot analysis of S100A8 and REG3g in feces, (e) REG3g and DMBT1 in colonic epithelial cells, and
(f) LCN2 in colonic lamina propria. Data are representative of two experiments. Mean value is shown±s.d. *Po0.05, **Po0.01. DMBT1, deleted in malignant tumor 1;
LCN2, lipocalin 2; MIF, migration inhibitory factor; REG, regenerating protein.
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including S100A8/A9 (Po0.001, 43% upregulation), MIF
(Po0.001, 138% upregulation), and PAP (Po0.05, 49%
upregulation; Figure 4a).
26–28 Of note, we also demonstrated
that LCN2 (Po0.001, 520% upregulation) and CCL20
(Po0.001, 1280% upregulation) were increased in sera
Figure2 ExpressionproﬁlesofthecandidatebiomarkersinaT-cell-dependentmousecolitismodel:preventiveandtherapeutictreatmentwithanti-interleukin(IL)-23(p19).
(a) Real-time reverse-transcription PCR (real-time RT-PCR) of transcript levels in colon tissue. Bir14 CD4þ T cells or control anti-CD3T cells were transferred intravenously
intoC3H.SCIDmice,andanti-IL-23p19mAborcontrolmAbwasadministeredintraperitoneally(100mg/mouse)onthesamedayofcelltransferandweeklythereafter.Allmice
were killed 8 weeks after cell transfer. (b) Bir14 CD4þ T cells or control anti-CD3T cells were transferred into C3H/HeJ SCID mice intravenously. Group 1 was killed after
4 weeks to assess that a colitis was present. Then, groups 2 and 3 were administered either isotype control or anti-IL-23(p19) mAbs at 100mg/mouse weekly for 4 weeks.
Real-time RT-PCR of the markers was performed twice with groups of 3 and 4 mice each time. Results are presented relative to ubiquitin transcripts (RU, relative units).
Bars indicate the median values. *Po0.05, **Po0.01 and ***Po0.001.
Figure 3 Regulation of the candidatebiomarkers by interleukin (IL)-17A,IL-22 and tumor necrosisfactor-a (TNF-a) in HT-29 humancolonicepithelial cells. HumanHT29
colonic epithelial cells were incubated with IL-23 (50ng/ml), IL-22, IL-17A, and/or TNF-a at 20ng/ml for 24–48h. (a) Expression levels were measured by real-time reverse-
transcription PCR (real-time RT-PCR) analysis. Results are shown as expression relative to ubiquitin mRNA levels (RU, relative units). (b) The protein accumulation was
measured in cell supernatant by enzyme-linked immunosorbent assay (ELISA). Error bars represent s.d.; data are representative of 3 experiments. DMBT1, deleted in
malignant tumor 1; LCN2, lipocalin 2; PAP, pancreatitis-associated protein.
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(Figure 4a). Further, we showed that the transcripts of
S100A8/A9, CCL20/MIP-3a, DMBT1, PAP, and LCN2 were
similarly upregulated in biopsies from the inﬂamed colon
of patients with CD, and markedly decreased in biopsy
samples from patients in remission (Figure 4b). As previously
described, we conﬁrmed that IL-22, IL-17A, and TNF-a
expression was upregulated in colon tissue from patients
with active CD
29–31 and downregulated in the remis-
sion group, but only IL-22 was signiﬁcantly decreased
Figure 4 Expression of potential interleukin(IL)-23-associated biomarkers in patients with Crohn’s disease. (a) Serum concentrations were measured by enzyme-linked
immunosorbent assay (ELISA) in normal control subjects (N¼18) and Crohn’s disease (CD) patients (N¼17). Bars indicate the median values. (b) Real-time reverse-
transcription PCRfortheexpression ofthecandidatebiomarkers incolontissuebiopsiesfromnormalcontrolsubjects(N¼6–7),CD active(N¼6–7),andremissionpatients
(N¼6). Results are presented relative to ubiquitin transcripts (RU, relative units). Bars indicate the median values. *Po0.05, **Po0.01, and ***Po0.001. (c) Fecal
concentrations were measured by ELISA in normal control subjects (N¼20) and CD patients (N¼11). Bars indicate the median values. *Po0.05, **Po0.01. DMBT1,
deleted in malignant tumor 1; LCN2, lipocalin 2; MIF, migration inhibitory factor; PAP, pancreatitis-associated protein.
Anti-IL-23 Efﬁcacy Biomarkers in IBD
Cayatte et al.
7
Clinical and Translational Gastroenterology(Supplementary Figure S6). We also conﬁrmed in human
feces that S100A8/A9 was upregulated in CD patients
(Po0.01, 887%) compared with controls and showed for
the ﬁrst time that PAP (Po0.05, 401%) and LCN2 (Po0.01,
783%) were also statistically upregulated in CD (Figure 4c).
Serum and fecal values for all individuals were entered
into JMP statistical software without any information about the
disease status. JMP then predicted the disease status for
each individual. In serum, based on LCN2 measurements
alone, four individuals were misclassiﬁed out of 35 (88%
conﬁdence), whereas based on LCN2 and PAP measure-
mentstakentogether,twoindividualsweremisclassiﬁed(94%
conﬁdence). But most importantly, when LCN2, PAP, and
CCL20 measurements were all taken into consideration, only
oneindividual was misclassiﬁedthereforerepresenting a 97%
conﬁdence and emphasizing the power of a biomarker panel
over single analyte measurement (Supplementary Table S3).
In addition, in feces, the measurement of S100A8/A9, LCN2,
and PAP showed a conﬁdence of 94% in discriminating
between normal and CD patients (94% conﬁdence, Supple-
mentary Table S3).
DISCUSSION
IL-23R inactivation blocks IBD. In this study, we used
the anti-CD40-induced mouse model for IBD to search for
efﬁcacy biomarkers of treatment by mAbs to IL-23R. Anti-
CD40 treatment induced a strong activation of inﬂam-
matory dendritic cells and macrophages, resulting in colon
inﬂammation, epithelial cell hyperplasia, and myeloid cell
accumulation in the lamina propria. We demonstrated that
IL-23R inactivation by neutralizing mAbs completely
prevented the development of colitis. Our results are consis-
tent with those of Uhlig et al.,
8 who showed that CD40-
induced inﬂammation was prevented by treatment with mAbs
to IL-23(p19). Overall, no signiﬁcant difference was observed
on the prevention of weight loss, inﬂammation of the colonic
laminia propria, and cytokines, and chemokines levels
blocking IL-23R versus p19 itself.
IL-22 and IL-17. IL-22 was upregulated 24h after colitis was
triggered by CD40 stimulation in our model, and anti-IL23R
treatment completely prevented this in the serum and the
colon tissue, suggesting that IL-23 signaling is indispensable
in promoting IL-22 production. IL-22 serum concentrations
are increased in CD patients and correlate with disease
activity and IL-23R genotype status
32 and correspondingly,
we also demonstrated that IL-22 transcripts increase during
active disease, and revert back to control values in patients
in remission. However, IL-22 protein is often undetectable
in serum from healthy individuals and not systematically
detectable in CD patients, making this proximal target-
engagement biomarker hard to use as an index of disease
clinically. IL-17A, another cytokine directly downstream of
our target, is a hallmark of CD, but we showed that IL-17A
does not vary consistently with CD and remission states.
Moreover, IL-17A is also difﬁcult to detect in serum from
CD patients, therefore limiting its utility in the clinic.
33
Nevertheless, IL-17A can be detected in the feces of
patients with active CD, but at a very low levels.
33
Antimicrobial proteins S100A8, S100A9, REG3b and c,
LCN2, and DMBT1. We demonstrated that the concentra-
tions of the antimicrobial proteins S100A8, S100A9, REG3b,
REG3g, and LCN2 were induced in the colon tissue of
diseased mice with T-cell-independent and T-cell-dependent
colitis, and that treatment by mAbs to IL-23R prevented
these upregulations, likely through the downregulation of
IL-22, IL-17A, and TNF-a. We showed in vitro that, in human
colonic epithelial cell line HT-29, stimulation with IL-22,
IL-17A, and/or TNF-a led to upregulation of the expression
of these markers, supporting the role of the IL-23/TH17
pathway as a key component of mucosal immunity.
20
We showed that several antimicrobial proteins were
candidate biomarkers for IL-23 blockage efﬁcacy. S100A8
and A9, termed calprotectin when complexed together, are
calcium-binding proteins expressed in abundance by acti-
vated neutrophils or epithelial cells that exhibit chemo-
attractant properties.
34 Calprotectin measurement by ELISA
in feces has been approved by the FDA (Food and Drug
Administration) to assess the level of gut inﬂammation in IBD
and monitor response to therapy (http://www.accessdata.fda.
gov/cdrh_docs/pdf5/k050007.pdf). S100A8/A9 also served
as a control for the different analysis methods used in the
present study.
REG3b and REG3g in mouse (PAP in human), which
belong to the secreted C-type lectin protein family, are
induced during gut bacterial colonization, and could partici-
pate in epithelial cell repair and protection during the onset of
inﬂammation.
28,35,36 PAP, previously shown to be upregu-
lated in gut biopsies and serum from CD patients compared
with controls, could act as an anti-inﬂammatory molecule
by inhibiting NF-kB, which controls cytokine production
and adhesion molecules in inﬂamed tissue.
28 Notably, REG
protein expression in the colon is IL-22 dependent through
STAT3 signaling.
37,38 Moreover, STAT3 and other down-
stream mediators of IL-23R such as JAK2 have been identi-
ﬁed as CD susceptibility genes.
39 Here, we show that PAP
expression is downregulated in CD patients in remission, and
statistically upregulated in feces from CD patients, making it
a potential biomarker for monitoring anti-IL-23 therapy.
LCN2, another antimicrobial protein expressed by immune
cells and colonic epithelial cells, exerts a bacteriostatic effect
by sequestering small iron-binding molecules synthesized by
bacteriaasameanofironacquisition.
40LCN2overexpression
is part of an IBD-speciﬁc gene signature established in patient
gut biopsies.
41,42 Here, we show that LCN2 is differentially
expressed in the serum and feces from CD patients when
compared with controls, and that its transcript levels vary with
disease activity in colon biopsies from patients in remission.
DMBT1 belongs to the superfamily of scavenger receptor
cysteine-rich genes. It mediates anti-inﬂammatory effects
during intestinal inﬂammation by aggregating Gram-positive
and -negative bacteria,
43 and by possibly decreasing NF-kB
signaling. Furthermore, DMBT1 gene expression is upregu-
latedingutbiopsiesfromCDpatients,andadeletionvariantof
DMBT1 may have a role in the pathogenesis of CD.
44 DMBT1
isa target forthe intracellular pathogen receptor NOD2,which
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blockade of IL-23 signaling decreased DMBT1 gene expres-
sion only in the T-cell-independent model. In human samples,
we conﬁrmed DMBT1 upregulation in colon biopsies from CD
patients compared with controls and demonstrated its down-
regulation with therapy. However, we failed to detect DMBT1
in mouse feces by western blot analysis, and it could not be
measured in serum due to the lack of reagents, restricting its
practical use.
MIF and CCL20. In addition to these antimicrobial proteins,
MIF, a pro-inﬂammatory cytokine, was upregulated in mouse
colon tissue.
45 MIF plasma concentration is upregulated
in CD patients, and anti-MIF treatment suppresses the
established colitis in a mouse T-cell transfer model.
27 We
conﬁrmed higher MIF serum concentration in CD patients
compared with normals, although the difference was not as
signiﬁcant as it was for calprotectin, PAP, LCN2, or CCL20.
CCL20 transcript was not upregulated in our mouse models
buthasbeen previouslyshowntobeoverexpressed incolonic
biopsies from CD patients and can regulate the chemotaxis
of T cells and dendritic cells in IBD.
46 CCR6, the receptor
of CCL20, has been recenthy identiﬁed as a CD susceptibility
gene.
39 Treatment of colonic explants with antibody to TNF-a
in vitro reduced CCL20 secretion in tissues from healthy
patientsbut not intissue from CD patients.
46 Our study results
could partially explain the latter as we show that IL-17A and
IL-22 are also able to control CCL20 expression. We con-
ﬁrmed the upregulation of CCL20 in colon biopsies from CD
patients compared with normals and showed a restoration
to control values in patients in remission. In addition, we
validated the upregulation of CCL20 in serum from CD
patients.
Overall remarks. We also demonstrated that in both a
T-cell-independent and -dependent mouse model of IBD, all
the markers track with IL-23 therapy both in a prophylactic
and importantly, a therapeutic manner. This highlights their
potential value in monitoring anti-IL-23 therapy, especially
since they are also increased in the inﬂamed colons of CD
patients and decreased in patients in remission. Last, we
found that the concentrations of most of the markers was
actually controlled by TNF-a, IL-22, and IL-17A in the gut,
suggesting that the therapeutic inhibition of IL-23 signaling,
which would lead to a decrease in IL-17A, IL-22, and TNF-a,
could be more effective than the inhibition of TNF-a alone.
Conclusion. In conclusion, proteomic analysis of fecal
proteins in disease and treatment mouse models allowed
us to uncover a number of potential disease- and target-
engagement biomarkers. Taken together, we conﬁrmed that
calprotectin, PAP, and MIF concentrations are higher in the
serum of CD patients than in healthy individuals, and we
added two CD-associated serum biomarkers to this list:
LCN2 and CCL20. We showed also for the ﬁrst time that PAP
and LCN2 were statistically upregulated in human feces
from CD patients. We believe that the measurement of these
markers as panels in both serum and stool will be helpful tool
to evaluate the response to anti-IL-23 therapy.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| IL-23 is a novel target for the treatment of IBD. Target
engagement and efﬁcacy biomarkers are necessary
for clinical trial monitoring.
| Calprotectin (S100A8/A9) measurement in feces is the
only FDA-approved biomarker to assess gut inﬂamma-
tion and response to therapy.
| PAP is upregulated in gut biopsies and serum from CD
patients compared to controls.
| LCN2 overexpression is part of an IBD-speciﬁc gene
signature from patients’ gut biopsies.
| DMBT1 and CCL20 gene expression is increased in
CD patients gut biopsies.
WHAT IS NEW HERE
| S100A8/A9,Reg3b,Reg3g,LCN2,DMBT1andMIFmRNA
levels correlate with disease score and dose titration of
mAbs to IL-23(p19) and IL-23R in a mouse model of colitis.
| PAP, LCN2, DMBT1 and CCL20 expression is down-
regulated in gut biopsies from CD patients in remission.
| CCL20 is increased in CD patients’ serum; PAP is
increased in patients’ feces. LCN2 is increased in both
serum and feces from CD patients.
| A combination of serum LCN2, PAP and CCL20, or
fecal calprotectin, LCN2 and PAP increased the ability
to discriminate between normal and CD patients to
97% and 94%, respectively.
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